Drugs / SIMUROSERTIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03708211 | Mar → Dec 2019 | neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02699749 | Mar 2016 → Dec 2019 | neoplastic disease or syndrome | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03261947 | Oct 2017 → Aug 2020 | colorectal cancer, malignant pancreatic neoplasm, neoplasm of esophagus, non-small cell lung carcinoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIMUROSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297644 ↗ |
| Known as | TAK-931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02699749 ↗ |
| Known as | TAK931F | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297644 ↗ |
| Action | Inhibit | “TAK-931, a cell division cycle 7 (CDC7) inhibitor” NCT02699749 ↗ |
| Modality | Small molecule | — CHEMBL4297644 ↗ |
| Route | Oral | “Patients ages ≥20 years received oral TAK-931” PMID 36970056 ↗ Nov 2022 |
| Target | CDC7 | “TAK-931, a cell division cycle 7 (CDC7) inhibitor” NCT02699749 ↗ |